Efficacy and Safety Results of a Drug-Free Cosmetic Fluid for Perioral Dermatitis: The Toleriane Fluide Efficacy in Perioral Dermatitis (TOLPOD) Study

Ehmann, Laura Maximiliane; Reinholz, Markus; Maier, Tanja; Lang, Martin; Wollenberg, Andreas

doi:10.5021/ad.2014.26.4.462

Cited by 4 publications

(4 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Several other, less well‐controlled studies have evaluated topical metronidazole and erythromycin, as well as some systemic antibiotics . The clinical value of twice daily application of a drug‐free cosmetic fluid has also been reported …”

Section: Introductionmentioning

confidence: 99%

Efficacy of a skin care cream with TRPV1 inhibitor 4‐t‐butylcyclohexanol in the topical therapy of perioral dermatitis

Srour

Bengel

Linden

et al. 2019

J of Cosmetic Dermatology

Self Cite

View full text Add to dashboard Cite

Background: Perioral dermatitis is a clinically distinctive reaction pattern of facial dermatitis, including redness, dryness, burning, pruritus and skin tightness. A gold standard treatment remains unclear.Objectives: Our study evaluates the clinical value of a skin care cream with the transient receptor potential vanilloid type 1 inhibitor 4-t-butylcyclohexanol in POD patients over 8 weeks.Methods: This open, unblinded 8-week clinical trial included 48 patients. A skin care cream containing 4-t-butylcyclohexanol was applied over a period of 8 weeks.Standardized questionnaires were used at baseline, 4 and 8 weeks, for history documentation, objective and subjective severity scores, and quality of life assessments.Six different skin physiology parameters were assessed at all timepoints. Results:The perioral dermatitis severity score decreased significantly during the treatment period. This was mirrored by significantly lower patients' subjective numerical rating score and an improved quality of life score. Transepidermal water loss, stratum corneum hydration and skin erythema improved significantly during the treatment period. Conclusion:This transient receptor potential vanilloid type 1 inhibitor-based skin care cream improved subjective and objective parameters of perioral dermatitis.Decreased transepidermal water loss values and increased stratum corneum hydration demonstrate a restored skin barrier function. Consequently, the topical inhibition of these receptors is a promising management option for POD. K E Y W O R D S perioral dermatitis, POD severity index, topical therapy, transepidermal water lossThis is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

show abstract

Section: Introductionmentioning

confidence: 99%

Efficacy of a skin care cream with TRPV1 inhibitor 4‐t‐butylcyclohexanol in the topical therapy of perioral dermatitis

Srour

Bengel

Linden

et al. 2019

J of Cosmetic Dermatology

Self Cite

View full text Add to dashboard Cite

show abstract

“…Conversely, asking to avoid using any skin care may not be considered acceptable by subjects with ACD signs and symptoms. 25,26 In parallel, the tested DC was very well tolerated, with no local side effects reported in addition to its significant benefit in improving signs and symptoms of skin intolerant to skin care products or sensitive skin, which may add to its benefit and is, therefore, another argument for using a specific DC in this type of subject profile. One limitation is that the subjects were not asked to report the daily use of the tested DC.…”

Section: Discussionmentioning

confidence: 92%

A Dermocosmetic Significantly Reduces the Frequency and Intensity of Facial Skin Intolerability and Sensitivity in Subjects with Skin Intolerant to Skin Care Products and Sensitive Skin

Kerob,

Czermanska,

Karamon

et al. 2023

CCID

View full text Add to dashboard Cite

Introduction Intolerance to dermocosmetics is frequent in subjects with allergic contact dermatitis (ACD). A dermocosmetic (DC) was developed to restore the natural skin barrier, to reduce skin inflammation and to improve sensitive skin in ACD. Objective To assess the benefit of a DC in subjects with an allergic background and intolerance to cosmetic care, or with sensitive skin. Materials and Methods In this open-label study, 107 subjects above 16 years of age applied DC on the face twice a day for 28 days. Assessments at Days 0, 14 and 28, included skin sensitivity, stinging test, local tolerance, transepidermal water loss (TEWL), skin hydration, inflammatory biomarkers (IL-1α, IL-1RA, PGE2) using tape stripping and subject satisfaction. Results 88% were women and mean age was 42.0±15.0 years. Skin sensitivity at inclusion scored 5.9±0.35; 46% had ACD, 95% skin irritation, 92% sensitive skin and 88% intolerance to cosmetics. A significant (p<0.0001) 85% decrease of frequency and intensity of the composite score was observed at both endpoints. Stinging scores significantly (p<0.0001) decreased from 3.9 at baseline to 2.4 at Day 14 and 1.4 at Day 28; 77% and 81% of subjects reported improved skin reactivity at Day 14 and Day 28, respectively. Similar improvements were noted in the frequency and intensity of irritation, erythema, stinging, burning and discomfort. TEWL, skin hydration and inflammatory biomarker levels significantly (p<0.0001) improved. Overall subject satisfaction (85%) and tolerance (investigators: 99%, subjects: 97%) were high. Conclusion DC significantly reduced the frequency and intensity of facial skin intolerability and sensitivity in subjects with skin intolerant to skin care products. Clinicaltrials.gov Identifier NCT05487937.

show abstract

“…After removal of duplicates, 563 records were screened. Thirty-two reports were sought, of which four are awaiting classification, [33][34][35][36] and 16 were excluded with reasons 2,8,[43][44][45][46][47][48]10,12,[37][38][39][40][41][42] (Appendix S3, Supporting Information). Eleven studies 6,7,52,9,11,24,25,29,[49][50][51] were included (see Appendix S4, Supporting Information).…”

Section: Resultsmentioning

confidence: 99%

Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review

Gray

Tod

Rohwer

et al. 2021

Acad Dermatol Venereol

View full text Add to dashboard Cite

The plethora of pharmacologic treatments used for periorificial dermatitis (POD) makes clinical decision‐making challenging. The objectives of this review were to assess the efficacy and safety of pharmacological interventions for POD in children and adults. The search was performed on 2 February 2021 and included seven databases and trial registries, with no date or language restrictions Study selection, data extraction and risk of bias assessments were performed independently and in duplicate by two authors, in accordance with a prespecified protocol. Meta‐analyses were performed and reported in accordance with PRISMA guidelines. Where meta‐analysis was not possible, a narrative synthesis was performed and reported in accordance with SWiM guidelines. The certainty of evidence was assessed using the Grading of Recommendation, Assessment, Development and Evaluation approach. Eleven studies representing 733 participants were included. Oral tetracycline may improve physician‐reported severity of POD from day 20 onwards (low certainty evidence). Adverse effects may include abdominal discomfort, facial dryness and pruritus. Pimecrolimus cream may improve physician‐reported severity slightly after 4 weeks of treatment (MD −0.49, 95% CI −1.02 to 0.04, n = 164, low certainty evidence). Adverse effects may include erythema, herpes simplex virus infection, burning and pruritus. Azelaic acid gel may result in no change in either physician‐ or patient‐reported severity after 6 weeks of treatment. The evidence is very uncertain about the effect of praziquantel ointment on physician‐reported severity and skin‐related quality of life after 4 weeks of treatment. The evidence is also very uncertain about the effect of topical clindamycin/benzoyl peroxide on physician‐reported severity. The body of evidence to inform treatment of POD currently consists of low and very low certainty evidence for important outcomes. Well‐designed trials are needed to further investigate treatment options. Data are required for children and from low‐middle income countries to improve external validity. Future trials should also include adequate post‐treatment follow‐up and standardized outcome measures.

show abstract

Efficacy and Safety Results of a Drug-Free Cosmetic Fluid for Perioral Dermatitis: The Toleriane Fluide Efficacy in Perioral Dermatitis (TOLPOD) Study

Cited by 4 publications

References 10 publications

Efficacy of a skin care cream with TRPV1 inhibitor 4‐t‐butylcyclohexanol in the topical therapy of perioral dermatitis

Efficacy of a skin care cream with TRPV1 inhibitor 4‐t‐butylcyclohexanol in the topical therapy of perioral dermatitis

A Dermocosmetic Significantly Reduces the Frequency and Intensity of Facial Skin Intolerability and Sensitivity in Subjects with Skin Intolerant to Skin Care Products and Sensitive Skin

Pharmacological interventions for periorificial (perioral) dermatitis in children and adults: a systematic review

Contact Info

Product

Resources

About